Stay updated on Low Dose Sulindac & Eflornithine for FAP Clinical Trial
Sign up to get notified when there's something new on the Low Dose Sulindac & Eflornithine for FAP Clinical Trial page.

Latest updates to the Low Dose Sulindac & Eflornithine for FAP Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the details of a phase III study on Familial Adenomatous Polyposis (FAP), including its purpose, inclusion and exclusion criteria, and the study director's name. A new version number has been added.SummaryDifference32%
- Check33 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check77 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check91 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check98 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Low Dose Sulindac & Eflornithine for FAP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Low Dose Sulindac & Eflornithine for FAP Clinical Trial page.